SCHEMBL40943

SCHEMBL40943

OCCN1CCN(c2cc(CO)cc(Nc3ncc4cc(-c5cc(O)ccc5Cl)ccc4n3)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 9/20 0.49
JAK2 O60674 4/20 0.44
JAK1 P23458 3/20 0.44
FGFR2 P21802 1/20 0.41
JAK3 P52333 2/20 0.40
STAT6 P42226 1/20 0.40
WEE1 P30291 1/20 0.39
EGFR P00533 2/20 0.38
ABL1 P00519 2/20 0.38
YES1 P07947 2/20 0.38
KDR P35968 2/20 0.38
LCK P06239 2/20 0.38
HCK P08631 1/20 0.38
MYLK4 Q86YV6 1/20 0.38
STK17A Q9UEE5 1/20 0.38
BRAF P15056 2/20 0.37
CIT O14578 1/20 0.37
GAK O14976 1/20 0.37
EPHB6 O15197 1/20 0.37
RIPK2 O43353 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL41155 0.91 SRC (0.52) SRCJAK2JAK1FGFR2WEE1
SCHEMBL41314 0.84 BRAF (0.42) SRCEGFRABL1BRAFPDGFRB
SCHEMBL41600 0.81 SRC (0.44) SRCJAK2JAK1JAK3ABL1
SCHEMBL42295 0.78 BRAF (0.43) SRCABL1BRAFPDGFRB
SCHEMBL14936291 0.77 SRC (0.43) SRCABL1KDRLCKHCK
SCHEMBL46422 0.76 GAK (0.49) SRCJAK2JAK1FGFR2WEE1
SCHEMBL229860 0.74 BRAF (0.68) SRCABL1YES1KDRLCK
SCHEMBL226245 0.74 SRC (0.67) SRCABL1YES1KDRLCK
SCHEMBL42013 0.74 BRAF (0.43) SRCABL1BRAFPDGFRB
SCHEMBL40938 0.73 SRC (0.40) SRCABL1YES1KDRLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103140480-A Heterocyclic compounds, their preparation and their therapeutic use FOVEA PHARMACEUTICALS 2013-06-05 CN claimed
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 US claimed
EP-2585439-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Fovea Pharmaceuticals (FR) 2013-05-01 EP claimed
WO-2011161159-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2011-12-29 WO claimed
CN-103140480-A Heterocyclic compounds, their preparation and their therapeutic use FOVEA PHARMACEUTICALS 2013-06-05 CN disclosed
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2013-05-16 US disclosed
EP-2585439-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION Fovea Pharmaceuticals (FR) 2013-05-01 EP disclosed
WO-2011161159-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION FOVEA PHARMACEUTICALS (FR) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123271-A1 HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THERAPEUTIC APPLICATION CAMK2D, CAMK2A, CAMK2B SRC 401/4885JAK2 283/4885JAK1 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.